Patents by Inventor Tuo WEI

Tuo WEI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12133924
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Grant
    Filed: December 11, 2023
    Date of Patent: November 5, 2024
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
  • Publication number: 20240261440
    Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.
    Type: Application
    Filed: January 22, 2024
    Publication date: August 8, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Tuo WEI, Yehui SUN, Qiang CHENG, Daniel SIEGWART
  • Publication number: 20240245618
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: August 3, 2023
    Publication date: July 25, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
  • Publication number: 20240245620
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: February 28, 2024
    Publication date: July 25, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
  • Publication number: 20240216515
    Abstract: Described herein are compositions, kits, and methods for potent delivery to a ceil of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. Tire lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 4, 2024
    Inventors: Michael Torres, Daniel J. Siegwart, Jackson Eby, Rumpa Bhattacherjee, Brandon Wustman, Vladimir Kharitonov, Qiang Cheng, Tuo Wei
  • Publication number: 20240148666
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: December 11, 2023
    Publication date: May 9, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
  • Publication number: 20230320994
    Abstract: Ionizable phospholipids and compositions and methods relating thereof are provided herein. In some aspects, the ionizable phospholipids provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
    Type: Application
    Filed: August 23, 2021
    Publication date: October 12, 2023
    Inventors: Daniel J. SIEGWART, Shuai LIU, Xueliang YU, Qiang CHENG, Tuo WEI
  • Patent number: 11766408
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: September 26, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
  • Patent number: 11648210
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Grant
    Filed: September 4, 2022
    Date of Patent: May 16, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
  • Patent number: 11648209
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Grant
    Filed: June 14, 2022
    Date of Patent: May 16, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
  • Patent number: 11590085
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: February 28, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
  • Publication number: 20230026843
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: September 4, 2022
    Publication date: January 26, 2023
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
  • Publication number: 20220387337
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: June 14, 2022
    Publication date: December 8, 2022
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
  • Patent number: 11510880
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: November 29, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
  • Publication number: 20220233460
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: April 1, 2022
    Publication date: July 28, 2022
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
  • Publication number: 20220133637
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: January 10, 2022
    Publication date: May 5, 2022
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
  • Patent number: 11304911
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: April 19, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
  • Publication number: 20220071916
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: March 4, 2021
    Publication date: March 10, 2022
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
  • Patent number: 11229609
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: January 25, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
  • Publication number: 20210401762
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: September 13, 2021
    Publication date: December 30, 2021
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART